The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.